New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials.
J Clin Exp Hepatol
; 9(4): 522-538, 2019.
Article
en En
| MEDLINE
| ID: mdl-31516269
AE, adverse event; CI, confidence interval; DAA, direct-acting antiviral agent; HCC, hepatocellular carcinoma; HCV, Hepatitis C virus; NNPIs, nonnucleoside polymerase inhibitors; NPIs, nucleoside polymerase inhibitors; PEG-IFN, pegylated interferon; PrIs, protease inhibitors; RAVs, resistance-associated variants; RBV, Ribavirin; RCT, randomized controlled trial; RR, risk ratio; SAEs, serious adverse events; SE, standard error; SVR, sustained virological response; hepatitis C; liver; meta-analysis; outcome research; systematic review
Texto completo:
1
Bases de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
/
Systematic_reviews
Idioma:
En
Revista:
J Clin Exp Hepatol
Año:
2019
Tipo del documento:
Article
País de afiliación:
Italia